[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541355":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":203,"collaborators":19,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":19,"eligibilityCriteria":211,"healthyVolunteers":207,"sex":212,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":19,"studyType":218,"phases":219,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},{"fullName":5,"class":6},"Cabaletta Bio","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CABA-201","EXPERIMENTAL","Severe Skin Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with severe skin involvement\n\nOrgan Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with organ involvement",[13],"Biological: CABA-201",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Medical Director","STUDY_DIRECTOR",[25],{"name":5,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","267 759 3100","4444","clinicaltrials@cabalettabio.com",[31,53,70,87,100,117,135,151,167,182],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Yale University","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-72.92816,41.30815,{"lat":43,"lon":42},[46,50],{"name":47,"role":26,"phone":48,"phoneExt":19,"email":49},"Stephanie Perez","860-992-2908","s.perez@yale.edu",{"name":51,"role":52,"phone":19,"phoneExt":19,"email":19},"Dr. Monique Hinchcliff, MD, MS","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":33,"city":55,"state":56,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Mayo Clinic Florida","Jacksonville","Florida","55905",{"type":40,"coordinates":59},[60,61],-81.65565,30.33218,{"lat":61,"lon":60},[64,68],{"name":65,"role":26,"phone":66,"phoneExt":19,"email":67},"Wesley Dillinger","904-953-4511","dillinger.wesley@mayo.edu",{"name":69,"role":52,"phone":19,"phoneExt":19,"email":19},"Dr. Andy Abril, MD",{"facility":71,"status":33,"city":72,"state":73,"zip":74,"country":37,"countryCode":38,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Northwestern Memorial Hospital","Chicago","Illinois","60611",{"type":40,"coordinates":76},[77,78],-87.65005,41.85003,{"lat":78,"lon":77},[81,85],{"name":82,"role":26,"phone":83,"phoneExt":19,"email":84},"Kaitlin King","312-695-0990","autoimmunesct@nm.org",{"name":86,"role":52,"phone":19,"phoneExt":19,"email":19},"Dr. George Georges, MD",{"facility":88,"status":33,"city":72,"state":73,"zip":89,"country":37,"countryCode":38,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"The University of Chicago Medical Center","60637",{"type":40,"coordinates":91},[77,78],{"lat":78,"lon":77},[94,98],{"name":95,"role":26,"phone":96,"phoneExt":19,"email":97},"Dequana Jones","773-834-5726","Dequana.Jones@bsd.uchicago.edu",{"name":99,"role":52,"phone":19,"phoneExt":19,"email":19},"Dr. Michael Macklin, MD",{"facility":101,"status":33,"city":102,"state":103,"zip":104,"country":37,"countryCode":38,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":40,"coordinates":106},[107,108],-94.62746,39.11417,{"lat":108,"lon":107},[111,115],{"name":112,"role":26,"phone":113,"phoneExt":19,"email":114},"Theresa Howard","913-588-0653","Thoward2@kumc.edu",{"name":116,"role":52,"phone":19,"phoneExt":19,"email":19},"Dr. Paul Schmidt, MD",{"facility":118,"status":33,"city":119,"state":120,"zip":121,"country":37,"countryCode":38,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"University of Michigan","Ann Arbor","Michigan","48109",{"type":40,"coordinates":123},[124,125],-83.74088,42.27756,{"lat":125,"lon":124},[128,131,133],{"name":129,"role":26,"phone":19,"phoneExt":19,"email":130},"Lynne Bischoff","lloisros@med.umich.edu",{"name":19,"role":26,"phone":19,"phoneExt":19,"email":132},"ssc-coordinator@umich.edu",{"name":134,"role":52,"phone":19,"phoneExt":19,"email":19},"Monalisa Ghosh, MD",{"facility":136,"status":33,"city":137,"state":138,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Mayo Clinic Rochester","Rochester","Minnesota",{"type":40,"coordinates":140},[141,142],-92.4699,44.02163,{"lat":142,"lon":141},[145,149],{"name":146,"role":26,"phone":147,"phoneExt":19,"email":148},"Christi Sagen","507-422-3425","sagen.christine@mayo.edu",{"name":150,"role":52,"phone":19,"phoneExt":19,"email":19},"Ashima Makol, MD",{"facility":152,"status":33,"city":153,"state":153,"zip":154,"country":37,"countryCode":38,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Columbia University Irving Medical Center","New York","10032",{"type":40,"coordinates":156},[157,158],-74.00597,40.71427,{"lat":158,"lon":157},[161,165],{"name":162,"role":26,"phone":163,"phoneExt":19,"email":164},"Gaby Ycaza","212-342-2751","mgy2107@cumc.columbia.edu",{"name":166,"role":52,"phone":19,"phoneExt":19,"email":19},"Elana Bernstein, MD",{"facility":168,"status":33,"city":137,"state":153,"zip":169,"country":37,"countryCode":38,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"University of Rochester","14642",{"type":40,"coordinates":171},[172,173],-77.61556,43.15478,{"lat":173,"lon":172},[176,180],{"name":177,"role":26,"phone":178,"phoneExt":19,"email":179},"Chelsey LoMonaco","585-402-2916","Chelsey_lomonaco@urmc.rochester.edu",{"name":181,"role":52,"phone":19,"phoneExt":19,"email":19},"Benjamin Korman, M.D.",{"facility":183,"status":33,"city":184,"state":185,"zip":186,"country":37,"countryCode":38,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Duke University","Durham","North Carolina","27710",{"type":40,"coordinates":188},[189,190],-78.89862,35.99403,{"lat":190,"lon":189},[193,197,201],{"name":194,"role":26,"phone":195,"phoneExt":19,"email":196},"Khalia Stewart","919-660-2280","Khalia.stewart@duke.edu",{"name":198,"role":26,"phone":199,"phoneExt":19,"email":200},"Michelle Mack","919-613-1107","Michelle.mack@duke.edu",{"name":202,"role":52,"phone":19,"phoneExt":19,"email":19},"Ankoor Shah, MD",{"type":204,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100541355","phase-1-reset-ssc-an-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-201-a-cd19-car-t-cell-therapy-in-subjects-with-systemic-sclerosis-100541355",false,"NCT06328777","RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis","Inclusion Criteria:\n\n* Age ≥18 and ≤75\n* A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Early active disease\n* Evidence of significant skin, pulmonary, renal, or cardiac involvement\n\nExclusion Criteria:\n\n* Contraindication to leukapheresis\n* History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites\n* Active infection requiring medical intervention at screening visit\n* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.\n* Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures\n* Severe lung or cardiac impairment\n* Previous CAR T cell therapy\n* Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","75 Years",{"count":216,"type":217},12,"ESTIMATED","INTERVENTIONAL",[220,221],"PHASE1","PHASE2","RESET-SSc: A Phase 1\u002F2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis",[224,225],"Systemic Sclerosis","Scleroderma",[9,227,228,229,230],"autoimmune disease","anti-CD19 CAR-T therapy","systemic sclerosis","scleroderma","2026-05-13",{"date":233,"type":234},"2026-05-14","ACTUAL",{"date":236,"type":234},"2024-07-02",{"date":238,"type":217},"2029-07",{"name":5,"class":6},10]